RxDoctor Payments Data

Jami Castellucci

Family · Fredericksburg, VANPI 1700488087

Payments from drug & device makers

$8,485in general payments, 2019–2025

Across 482 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Pfizer$698
  • Amgen$695
  • Lilly USA, LLC$618
  • GSK$432
  • plus $3K from 51 others

What the payments were for

  • Food & beverage$8,485100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,485 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$57,028
Medicare patients
205
Services billed
833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin92$119,262
OzempicSemaglutide54$99,373
JanuviaSitagliptin Phosphate34$53,216
FarxigaDapagliflozin Propanediol46$46,491
EliquisApixaban26$35,740
TrulicityDulaglutide11$25,691
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$19,767
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr34$19,440
LinzessLinaclotide25$18,863
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$13,163
XareltoRivaroxaban11$12,738
Combivent RespimatIpratropium/Albuterol Sulfate14$7,170
SavellaMilnacipran Hcl11$6,798
Bupropion XlBupropion Hcl57$5,691
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate39$5,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$346$126,432106 claims
Novo NordiskOzempic$1,139$99,37354 claims
MerckJanuvia$165$53,21634 claims
AstraZenecaFarxiga$152$46,49146 claims
GSKTrelegy Ellipta, Anoro Ellipta$432$39,20663 claims
PfizerEliquis$698$35,74026 claims
AbbVieLinzess, Savella, Synthroid$1,463$27,07953 claims
Lilly USA, LLCTrulicity$618$25,69111 claims
Johnson & JohnsonXarelto$58$12,73811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →